When does natalizumab’s patent expire?
Natalizumab’s exclusivity in the United States and Europe is driven by different layers of protection (drug patents, method/combination patents, and regulatory exclusivity). The provided information does not include the specific patent numbers, jurisdictions, or dates needed to determine an exact “patent expiry” date.
What counts as “patent expiry” for natalizumab (and why dates can differ)?
For biologics like natalizumab, “expiry” can mean different things:
- Core drug patents (cover the molecule or key manufacturing/characterization aspects).
- Secondary patents (often for dosing regimens, use in specific diseases, formulations, or manufacturing processes).
- Regulatory exclusivity (which can extend market protection even after some patents expire).
Because these layers don’t all end on the same date, the first date a biosimilar can launch can differ from the last patent expiry date.
Can biosimilars enter before every natalizumab patent ends?
Yes—if a biosimilar can rely on approval pathways and does not infringe the still-active patents it would otherwise implicate, it may be able to seek approval and/or launch earlier than the last remaining patent. Launch timing depends on:
- Which patents are listed in the relevant regulatory/market-protection lists for that country.
- Whether litigation triggers “automatic” stay/entry restrictions.
- The specific product’s route of approval and how infringement is assessed.
Why the exact expiry date depends on the country
Natalizumab is marketed under Tysabri. Patent and exclusivity timelines vary by:
- Jurisdiction (U.S. vs EU vs UK vs others).
- Patent filing/priority dates and how those translate into local patent terms.
- Regulatory exclusivity rules in that jurisdiction.
What you can provide to get the exact expiry date
If you tell me:
1) the country/region (e.g., U.S., EU/EMA, UK), and
2) whether you want first biosimilar launch, last listed patent expiry, or marketing exclusivity end,
I can narrow it to the correct target date.
Sources: None provided in the prompt.